2020-03-26 16:00Financial Performance - In 2019, the company's operating income was CNY 1,604,333,866.54, representing a 2.94% increase from CNY 1,558,452,694.03 in 2018[15]. - The net profit attributable to shareholders was CNY 370,778,791.81, a decrease of 10.56% compared to CNY 414,540,417.19 in the previous year[15]. - The company's total assets increased by 38.67% to CNY 6,151,869,396.17 at the end of 2019, up from CNY 4,436,352,586.66 in 2018[15]. - The net assets attributable to shareholders grew by 51.04% to CNY 5,454,779,644.49, primarily due to the capital reserve increase from the IPO[18]. - The basic earnings per share decreased by 12.36% to CNY 2.27 in 2019, down from CNY 2.59 in 2018[16]. - The diluted earnings per share also stood at CNY 2.27, reflecting the same decrease as basic earnings per share[16]. - The weighted average return on equity decreased to 9.26%, down 2.91 percentage points from 12.17% in 2018[16]. - The gross profit margin for the reporting period was 77.28%, slightly down from 78.51% in 2018[57]. - The company achieved total revenue of RMB 1,604.33 million in 2019, representing a year-on-year increase of 2.94%[56]. - Main business revenue reached RMB 1,602.32 million, with a growth of 3.00% compared to 2018[56]. Research and Development - Research and development expenses accounted for 7.24% of operating income, an increase of 1.12 percentage points from 6.12% in 2018[16]. - The company has increased R&D investment, focusing on new technology and product development, as well as the transformation of core technological achievements[33]. - The company has established a comprehensive R&D project management system, emphasizing collaboration with renowned universities and research institutions[33]. - R&D investment for the period reached CNY 116,076,024.05, accounting for 7.24% of total revenue[40]. - The company has a dedicated R&D team of 263 members, which constitutes 19.66% of the total workforce, including 20 PhD holders and 67 master's degree holders[128]. - The company is focusing on developing third-generation hyaluronic acid and new animal-derived hemostatic drugs, among other projects[130]. - The company aims to expand its product range into areas such as dry eye syndrome and glaucoma treatment, leveraging its four major technology platforms[130]. - The company is actively pursuing collaborations with domestic and international research institutions to enhance its R&D capabilities and technology transfer[131]. Market Position and Products - The company is positioned as a leading enterprise in the field of biomedical materials in China, focusing on four major therapeutic areas[31]. - The market share of the company's ophthalmic viscoelastic device products was 46.87%, maintaining the leading position for 12 consecutive years[31]. - The company’s hyaluronic acid products "Haiwei" and "Jiaolan" have gained significant consumer recognition, ranking among the top in market share in the aesthetic medicine sector[31]. - The company’s orthopedic joint cavity viscoelastic supplement products achieved a market share of 39.67%, leading the market for 5 consecutive years[31]. - The company’s surgical anti-adhesion products held a market share of 48.85%, also maintaining the top position for 12 consecutive years[31]. - The company has developed a full range of products in the ophthalmology sector, leading the domestic market in artificial lenses[52]. - The company is the largest producer of orthopedic joint cavity viscoelastic supplements in China, with a market share of 39.67% in 2018[74]. - The company maintains a strong market position in the recombinant human epidermal growth factor sector, holding a market share of 20.39% in 2018[73]. Cash Dividend and Shareholder Policies - The company plans to distribute a cash dividend of RMB 7.00 per 10 shares, totaling RMB 124,491,710, which accounts for 33.58% of the net profit attributable to shareholders for 2019[5]. - The cash dividend policy requires a minimum distribution of 80% of profits for mature companies without major capital expenditure plans[172]. - In 2019, the company distributed a cash dividend of 7 RMB per 10 shares, totaling 124,491,710 RMB, which represents 33.58% of the net profit attributable to ordinary shareholders[176]. - The company has not proposed any cash profit distribution plan for the reporting period despite having positive distributable profits[177]. - The actual controller and shareholders have committed to not transferring or managing their shares for 36 months post-IPO[178]. Risk Management and Compliance - The company has detailed various risk factors that may affect its operations in the report[3]. - The company has a comprehensive risk management strategy outlined in the report[3]. - The company faces risks from intensified market competition and regulatory changes in the pharmaceutical industry, which could impact financial performance[88][89]. - The company has confirmed that there are no undisclosed related-party transactions, maintaining transparency in its financial dealings[184]. - The company has committed to adhering to all relevant laws and regulations regarding share transfers and related transactions, ensuring compliance[184]. Environmental and Social Responsibility - The company has emphasized its commitment to environmental protection, ensuring compliance with relevant laws and regulations without any environmental accidents[196]. - The total wastewater discharge during the reporting period was approximately 140,509.80 tons, with COD emissions totaling about 17.25 tons and ammonia nitrogen emissions around 0.43 tons[199]. - The company’s wastewater treatment facility has a capacity of 330 tons per day, and the facility is operating normally[198]. - The company’s air treatment facilities include a waste gas washing tower with a capacity of 10,000 cubic meters per hour, which is also operating normally[198]. - The company has implemented effective measures for noise reduction and pollution control, ensuring compliance with environmental standards[199].